Clinical Trial Update: Erlotinib and Docetaxel in Second Line of Treatment in Patients With Non Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial assessing erlotinib plus docetaxel as second-line therapy for non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)
• Taxotere (docetaxel)

Snippet

Sponsor: University Hospital, Limoges | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: COMPLETED